Key facts
- Pearl Diagnostics’s last known valuation is $15.0M (Jun 2022).
- It has raised $4.5M across 2 recorded rounds; the latest was Early Stage VC ($11.2M) in Mar 2026.
- Notable investors include Creative Destruction Lab, US National Science Foundation, TEDCO, CARB-X, John Cammack — 11 tracked in total.
- Pearl Diagnostics has filed 2 Form Ds with the SEC since 2022, most recently Apr 2026 ($11.2M sold to 21 investors).
- Status: Privately Held (backing).
- ·Post-money valuations for all 2 rounds
- ·The complete investor list — 11 names
- ·Watchlist + deal alerts for Pearl Diagnostics
Funding rounds
2 roundsAbout Pearl Diagnostics
Developer of in vitro diagnostic tests designed to aid diagnosis and screening for bacterial and fungal lung infections. The company uses proprietary and patented technology to detect microbial vesicles that are released during infection and excreted into urine, and detect fungal lung infections using interferon-gamma release technologies, enabling clinicians to detect the microbial cause of pneumonia using patented technology.
- Sector
- Healthcare
- HQ
- Baltimore, MD, United States
- Founded
- 2014
- Employees
- 9
- Website
- pearldx.com/
- Ownership
- Privately Held (backing)
Pearl Diagnostics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Pearl Diagnostics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Pearl Diagnostics in its N-PORT filings yet. We sweep new filings monthly.